🇺🇸 SECLakefront Biotherapeutics NVDoubao · 实盘不做把握 8/10不做原因:风险收益比不佳
北京时间·🕒 发布 04:36:50·⟳ 抓取 04:37:13 +23s·⚡ 决策 10-21 04:41:20 +4m07s·6.6 天前
Lakefront Biotherapeutics 公告完成2026年6月回购计划，10月12–16日回购107,804股、约285万欧元
这是外国发行人按规披露的回购交易周报：回购计划本身在2026年6月9日已宣布并被市场定价，本条仅确认10月12–16日的执行结果及计划已完成，没有新的、超出预期的资本回报承诺；金额约285万欧元、占公司体量微小，且公司为临床期生物科技（核心变量是gamgertamig等管线临床/BD进展），不具备短线正edge。
📄 原文Lakefront Biotherapeutics NV↗ 原文
----- f6k_102026.htm ----- 6-K 1 f6k_102026.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D…
不做 Lakefront Biotherapeutics NV（LKFT.US）
旧回购计划的例行执行与完结披露，无新增授权或基本面惊喜，单周约285万欧元量级微小且执行期影响已沉淀，无可交易边际edge（RISK_REWARD）
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
6-K附件只是6月已公告回购计划的执行明细与‘已完成’确认，属例行法定披露、无新增授权或基本面增量，量级约285万欧元，对临床期生物科技股价无实质驱动，不做。
🔎 新鲜度:最早出现 2026-10-20 · 扩散 low · price-in 风险 high ↗
关键理由
- 回购计划于2026-06-09已宣布，本条仅为10月12–16日历史执行的事后披露，预期差与新鲜度均不足
- 单周回购总额约285万欧元、累计库存股约198.5万股，无新增授权规模，边际供需影响微小
主要风险
- 公司为临床期生物科技，股价主要由gamgertamig等管线临床数据与BD交易驱动，回购披露可能被忽视，按此交易无统计edge
反向证据
- 做多前查反向 · 来源 filing · 日期 2026-10-20 · 影响 weakens
公告仅确认旧计划完成，未宣布新增或扩大回购，亦无管线/业绩正面增量，做多缺乏新催化
检索:Lakefront LKFT new buyback authorization / increased repurchase program 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:确认以AVOID处理，不为约285万欧元的例行回购设定tp/sl或仓位
方向:无足够同类对齐先例；但例行回购执行/完成披露普遍为中性，方向不依赖先例
涨幅量级:无高相似首发对齐样本，不用任何幅度数字；本条无新增授权，量级不支持定价
形态:回购计划的事前宣布才是事件点，事后执行周报通常无显著股价反应
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`lakefront biotherapeutics repurchase program completed october 2026 | lakefront buyback june 9 2026 program fully completed | lkft 107804 shares repurchased october 12-16 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent que
原文全文
展开原文 · 6,705 字
----- f6k_102026.htm -----
6-K
1
f6k_102026.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
Commission File Number:
001-37384
Lakefront Biotherapeutics
(Translation of registrant's name into English)
Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).
On October 20, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Exhibit 99.1. Press release dated October 20, 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Lakefront Biotherapeutics
(Registrant)
Date: October 20, 2026
/s/ Ying Deng
Ying Deng
Authorized Officer
----- exh_991.htm -----
EX-99.1
2
exh_991.htm
PRESS RELEASE
EdgarFiling
EXHIBIT 99.1
Acquisition of Own Shares
Mechelen, Belgium; October 20, 2026, 22.01 CEST; regulated information
Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext &
NASDAQ: LKFT) ("Lakefront") announces that between October 12, 2026, and October 16, 2026, it has repurchased 107,804 Lakefront shares
via a discretionary mandate to an independent financial intermediary, as follows:
Date
of purchase
Market/MTF
Number
of shares
Average
price paid (€)
Total
(€)
Lowest
price paid (€)
Highest
price paid (€)
10/12/2026
XAMS
20,818
26.51
551,843.54
26.38
26.68
10/12/2026
CEUX
4,350
26.56
115,543.40
26.44
26.68
10/12/2026
AQEU
429
26.55
11,391.15
26.44
26.58
10/12/2026
TQEX
186
26.53
4,935.12
26.44
26.62
10/13/2026
XAMS
20,811
26.36
548,480.15
26.16
26.52
10/13/2026
CEUX
2,446
26.41
64,590.05
26.30
26.50
10/13/2026
AQEU
1,896
26.41
50,081.13
26.30
26.52
10/13/2026
TQEX
634
26.37
16,717.06
26.30
26.46
10/15/2026
XAMS
23,113
26.49
612,304.97
26.04
26.98
10/15/2026
CEUX
3,219
26.26
84,545.75
26.14
26.92
10/15/2026
AQEU
1,520
26.22
39,859.26
26.16
26.88
10/15/2026
TQEX
333
26.13
8,701.02
26.12
26.30
10/16/2026
XAMS
24,946
26.57
662,730.40
26.18
26.76
10/16/2026
CEUX
2,287
26.63
60,909.67
26.28
26.78
10/16/2026
AQEU
65
26.46
1,719.90
26.46
26.46
10/16/2026
TQEX
751
26.65
20,013.10
26.40
26.80
Total
107,804
26.48
2,854,365.69
26.04
26.98
As of market close on October 16, 2026, Lakefront holds 1,985,157 of its own ordinary shares.
With these purchases, the repurchase program announced on June 9, 2026, has been fully completed.
About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building
a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage
portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell
engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront
identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term
shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.
For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1
412 522 6418
sherri.spear@lakefrontbio.com
Richie Livingston
+1 312 636 7072
richie.livingston@lakefrontbio.com
Forward-looking statements
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but
are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,”
“intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,”
“will,” “could,” “would,” “potential,” “forward,” “goal,” “next,”
“continue,” “should,” “encouraging,” “aim,” “progress,” “remain,”
“explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements
regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are
based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements
may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity,
performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance,
financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those
risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”),
including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC.
Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition,
even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such
forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking
statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking
statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically
required by law or regulation.
6-K
1
f6k_102026.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
Commission File Number:
001-37384
Lakefront Biotherapeutics
(Translation of registrant's name into English)
Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).
On October 20, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Exhibit 99.1. Press release dated October 20, 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Lakefront Biotherapeutics
(Registrant)
Date: October 20, 2026
/s/ Ying Deng
Ying Deng
Authorized Officer
----- exh_991.htm -----
EX-99.1
2
exh_991.htm
PRESS RELEASE
EdgarFiling
EXHIBIT 99.1
Acquisition of Own Shares
Mechelen, Belgium; October 20, 2026, 22.01 CEST; regulated information
Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext &
NASDAQ: LKFT) ("Lakefront") announces that between October 12, 2026, and October 16, 2026, it has repurchased 107,804 Lakefront shares
via a discretionary mandate to an independent financial intermediary, as follows:
Date
of purchase
Market/MTF
Number
of shares
Average
price paid (€)
Total
(€)
Lowest
price paid (€)
Highest
price paid (€)
10/12/2026
XAMS
20,818
26.51
551,843.54
26.38
26.68
10/12/2026
CEUX
4,350
26.56
115,543.40
26.44
26.68
10/12/2026
AQEU
429
26.55
11,391.15
26.44
26.58
10/12/2026
TQEX
186
26.53
4,935.12
26.44
26.62
10/13/2026
XAMS
20,811
26.36
548,480.15
26.16
26.52
10/13/2026
CEUX
2,446
26.41
64,590.05
26.30
26.50
10/13/2026
AQEU
1,896
26.41
50,081.13
26.30
26.52
10/13/2026
TQEX
634
26.37
16,717.06
26.30
26.46
10/15/2026
XAMS
23,113
26.49
612,304.97
26.04
26.98
10/15/2026
CEUX
3,219
26.26
84,545.75
26.14
26.92
10/15/2026
AQEU
1,520
26.22
39,859.26
26.16
26.88
10/15/2026
TQEX
333
26.13
8,701.02
26.12
26.30
10/16/2026
XAMS
24,946
26.57
662,730.40
26.18
26.76
10/16/2026
CEUX
2,287
26.63
60,909.67
26.28
26.78
10/16/2026
AQEU
65
26.46
1,719.90
26.46
26.46
10/16/2026
TQEX
751
26.65
20,013.10
26.40
26.80
Total
107,804
26.48
2,854,365.69
26.04
26.98
As of market close on October 16, 2026, Lakefront holds 1,985,157 of its own ordinary shares.
With these purchases, the repurchase program announced on June 9, 2026, has been fully completed.
About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building
a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage
portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell
engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront
identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term
shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.
For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1
412 522 6418
sherri.spear@lakefrontbio.com
Richie Livingston
+1 312 636 7072
richie.livingston@lakefrontbio.com
Forward-looking statements
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but
are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,”
“intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,”
“will,” “could,” “would,” “potential,” “forward,” “goal,” “next,”
“continue,” “should,” “encouraging,” “aim,” “progress,” “remain,”
“explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements
regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are
based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements
may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity,
performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance,
financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those
risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”),
including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC.
Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition,
even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such
forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking
statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking
statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically
required by law or regulation.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
349653e4dc· 2026-10-21 04:41 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前